The history of standardization relating to the activities of medical laboratories traces the development of quality system standards in the world, and their evolution. In this study, we have included the key benchmarks that represent the stages of the quality system’s evolution in recent decades. Accreditation of medical laboratories has become compulsory in most countries, regarding national or international standards. International acknowledgment of the effectiveness of the results delivered to the many stakeholders, particularly patients and prescribers, is conferred through the use of standards. The ISO 15189 standard represents the latest and most specific international standards for medical laboratories of all types. More research is necessary to study if laboratory practices reflect the evolution of standards within the medical laboratory field.
与医学实验室活动有关的标准化历史追溯了世界质量体系标准的发展及其演变。 在本研究中，我们纳入了代表近几十年来质量体系演变阶段的主要基准。在大多数国家，根据国家或国际标准，医学实验室的评审已成为强制性的。通过使用标准，向众多利益相关者（尤其是患者和处方者）提供的结果的有效性得到了国际认可。 ISO 15189 标准是适用于各类医学实验室的最新、最具体的国际标准。 有必要开展更多研究，以了解实验室实践是否反映了医学实验室领域标准的演变。
{"title":"Emergence and evolution of standardization systems in medical biology laboratories","authors":"Rita B. Khattar, Maha E. Nehme","doi":"10.1515/almed-2024-0014","DOIUrl":"https://doi.org/10.1515/almed-2024-0014","url":null,"abstract":"\u0000 \u0000 \u0000 The history of standardization relating to the activities of medical laboratories traces the development of quality system standards in the world, and their evolution.\u0000 \u0000 \u0000 \u0000 In this study, we have included the key benchmarks that represent the stages of the quality system’s evolution in recent decades. Accreditation of medical laboratories has become compulsory in most countries, regarding national or international standards. International acknowledgment of the effectiveness of the results delivered to the many stakeholders, particularly patients and prescribers, is conferred through the use of standards.\u0000 \u0000 \u0000 \u0000 The ISO 15189 standard represents the latest and most specific international standards for medical laboratories of all types.\u0000 \u0000 \u0000 \u0000 More research is necessary to study if laboratory practices reflect the evolution of standards within the medical laboratory field.\u0000","PeriodicalId":502333,"journal":{"name":"Advances in Laboratory Medicine / Avances en Medicina de Laboratorio","volume":"15 6","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141030698","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Patricia Ramos Mayordomo, Marta Capilla Díez, Danay Areli Ticona Espinoza, María Verónica Torres Jaramillo, Nathalie Martínez Tejeda, Thalia Gloria Ticona Espinoza, Cristina Colmenero Calleja, V. Fraile Gutiérrez
Thrombotic microangiopathy (TMA) is characterized by thrombocytopenia, microangiopathic hemolytic anemia and target organ damage. Pregnancy is associated with several forms of TMA, including preeclampsia (PE), HELLP syndrome, thrombotic thrombocytopenic purpura (TTP) and hemolytic uremic syndrome (HUS). When HUS is secondary to a deregulation of the alternative complement pathway, it is known as atypical HUS (aHUS). Differential diagnosis is challenging, as these forms share clinical characteristics. However, early diagnosis is crucial for a specific treatment to be established and improve prognosis. We present the case of a 43 year-old primiparous woman admitted to hospital for an urgent C-section at 33 gestational weeks due to a diagnosis of severe preeclampsia and fetal distress. In the immediate postpartum, the patient developed acute liver failure and anuric renal failure in the context of the HELLP syndrome, anemia, thrombocytopenia, arterial hypertension (HTN) and neurological deficit. TMA study and differential diagnosis confirmed pregnancy-associated aHUS. Treatment with eculizumab was initiated, with good response and progressive improvement of clinical and analytical parameters. aHUS is a rare multifactorial disease that used to be associated with high mortality rates before the advent of eculizumab. Due to challenging diagnosis, the clinical laboratory plays a major role in the differential diagnosis and management of the disease.
{"title":"Thrombotic microangiopathy (TMA) associated with pregnancy: role of the clinical laboratory in differential diagnosis","authors":"Patricia Ramos Mayordomo, Marta Capilla Díez, Danay Areli Ticona Espinoza, María Verónica Torres Jaramillo, Nathalie Martínez Tejeda, Thalia Gloria Ticona Espinoza, Cristina Colmenero Calleja, V. Fraile Gutiérrez","doi":"10.1515/almed-2024-0053","DOIUrl":"https://doi.org/10.1515/almed-2024-0053","url":null,"abstract":"\u0000 \u0000 \u0000 Thrombotic microangiopathy (TMA) is characterized by thrombocytopenia, microangiopathic hemolytic anemia and target organ damage. Pregnancy is associated with several forms of TMA, including preeclampsia (PE), HELLP syndrome, thrombotic thrombocytopenic purpura (TTP) and hemolytic uremic syndrome (HUS). When HUS is secondary to a deregulation of the alternative complement pathway, it is known as atypical HUS (aHUS). Differential diagnosis is challenging, as these forms share clinical characteristics. However, early diagnosis is crucial for a specific treatment to be established and improve prognosis.\u0000 \u0000 \u0000 \u0000 We present the case of a 43 year-old primiparous woman admitted to hospital for an urgent C-section at 33 gestational weeks due to a diagnosis of severe preeclampsia and fetal distress. In the immediate postpartum, the patient developed acute liver failure and anuric renal failure in the context of the HELLP syndrome, anemia, thrombocytopenia, arterial hypertension (HTN) and neurological deficit. TMA study and differential diagnosis confirmed pregnancy-associated aHUS. Treatment with eculizumab was initiated, with good response and progressive improvement of clinical and analytical parameters.\u0000 \u0000 \u0000 \u0000 aHUS is a rare multifactorial disease that used to be associated with high mortality rates before the advent of eculizumab. Due to challenging diagnosis, the clinical laboratory plays a major role in the differential diagnosis and management of the disease.\u0000","PeriodicalId":502333,"journal":{"name":"Advances in Laboratory Medicine / Avances en Medicina de Laboratorio","volume":"6 11","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-04-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140652872","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Castro-Castro María-José, Cachón-Suárez Isabel, Maestre-Fernández Andrea, Navarro-Badal Rosa
There is little literature on the interference of metamizole in measurement creatinine concentration by the enzymatic method. Some studies have postulated that the dipyrone molecule is responsible for interfering in the last reaction of the enzymatic method sequence, due to its similarity with the 4-aminophenazone molecule. The aim of this study is to examine the interference of the presence of metamizole in the measurement of serum creatinine concentration by the enzymatic method. An interference study of the measurement of creatinine concentration was carried out with two measurement procedures (enzymatic and Jaffe), by adding different concentrations of metamizole to pool from 30 serum samples of patients. The interference study indicates that the results of serum creatinine concentrations in patients, as measured by the enzymatic method, decrease with the addition of increasing concentrations of metamizole. There is interference with metamizole in the measurement of serum creatinine concentration by the enzymatic method that it is have not seen in the Jaffe method.
{"title":"Interference of metamizole in the measurement of serum creatinine concentration","authors":"Castro-Castro María-José, Cachón-Suárez Isabel, Maestre-Fernández Andrea, Navarro-Badal Rosa","doi":"10.1515/almed-2023-0163","DOIUrl":"https://doi.org/10.1515/almed-2023-0163","url":null,"abstract":"\u0000 \u0000 \u0000 There is little literature on the interference of metamizole in measurement creatinine concentration by the enzymatic method. Some studies have postulated that the dipyrone molecule is responsible for interfering in the last reaction of the enzymatic method sequence, due to its similarity with the 4-aminophenazone molecule. The aim of this study is to examine the interference of the presence of metamizole in the measurement of serum creatinine concentration by the enzymatic method.\u0000 \u0000 \u0000 \u0000 An interference study of the measurement of creatinine concentration was carried out with two measurement procedures (enzymatic and Jaffe), by adding different concentrations of metamizole to pool from 30 serum samples of patients.\u0000 \u0000 \u0000 \u0000 The interference study indicates that the results of serum creatinine concentrations in patients, as measured by the enzymatic method, decrease with the addition of increasing concentrations of metamizole.\u0000 \u0000 \u0000 \u0000 There is interference with metamizole in the measurement of serum creatinine concentration by the enzymatic method that it is have not seen in the Jaffe method.\u0000","PeriodicalId":502333,"journal":{"name":"Advances in Laboratory Medicine / Avances en Medicina de Laboratorio","volume":"8 24","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-04-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140652848","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
To investigate the role of body mass index (BMI), serum lipid profile molecules and their derivative indexes in colorectal polyps. A total of 352 individuals who underwent colonoscopy at our center were included in this retrospective analysis. Of these, 247 patients without evident abnormalities (control group), while 105 patients diagnosed with colorectal polyps (patient group). Serum lipid profile molecules and their derivative indexes were then compared between the two groups. The patient group exhibited significantly higher levels of total cholesterol (TC) and apolipoprotein B (ApoB) compared to the control group (p<0.05). In males, the patient group displayed elevated levels of ApoB and ApoB/ApoA1 ratio compared to the control group (p<0.05). Additionally, the triglycerides (TG) and TG/high-density lipoprotein-cholesterol (HDL-C) ratios were significantly higher in the multiple polyps group than in the single polyp group (p<0.05). Furthermore, the HDL-C and HDL-C/ApoA1 ratio levels were higher in the adenomatous polyp group when compared to the non-adenomatous polyp group (p<0.05). Multiple logistic regression analysis indicated that total cholesterol (TC), TG, low-density lipoprotein-cholesterol (LDL-C), TC/HDL-C ratio, TG/HDL-C ratio and LDL-C/HDL-C ratio were risk factors for the occurrence of colorectal polyps (p<0.05). ROC curve analyses revealed that TC, ApoB, and ApoB/ApoA1 ratio were associated with colorectal polyps. No significant difference in BMI between the two groups (p>0.05). The incidence and progression of colorectal polyps are linked to serum lipid molecules and their derivative indexes. Dyslipidemia may increase the risk of colorectal polyps, potentially leading to colorectal cancer (CRC).
{"title":"The role of BMI, serum lipid profile molecules and their derivative indexes in colorectal polyps","authors":"Chunyu Huang, Weipeng Liang, Yu‐ying Sun","doi":"10.1515/almed-2023-0170","DOIUrl":"https://doi.org/10.1515/almed-2023-0170","url":null,"abstract":"\u0000 \u0000 \u0000 To investigate the role of body mass index (BMI), serum lipid profile molecules and their derivative indexes in colorectal polyps.\u0000 \u0000 \u0000 \u0000 A total of 352 individuals who underwent colonoscopy at our center were included in this retrospective analysis. Of these, 247 patients without evident abnormalities (control group), while 105 patients diagnosed with colorectal polyps (patient group). Serum lipid profile molecules and their derivative indexes were then compared between the two groups.\u0000 \u0000 \u0000 \u0000 The patient group exhibited significantly higher levels of total cholesterol (TC) and apolipoprotein B (ApoB) compared to the control group (p<0.05). In males, the patient group displayed elevated levels of ApoB and ApoB/ApoA1 ratio compared to the control group (p<0.05). Additionally, the triglycerides (TG) and TG/high-density lipoprotein-cholesterol (HDL-C) ratios were significantly higher in the multiple polyps group than in the single polyp group (p<0.05). Furthermore, the HDL-C and HDL-C/ApoA1 ratio levels were higher in the adenomatous polyp group when compared to the non-adenomatous polyp group (p<0.05). Multiple logistic regression analysis indicated that total cholesterol (TC), TG, low-density lipoprotein-cholesterol (LDL-C), TC/HDL-C ratio, TG/HDL-C ratio and LDL-C/HDL-C ratio were risk factors for the occurrence of colorectal polyps (p<0.05). ROC curve analyses revealed that TC, ApoB, and ApoB/ApoA1 ratio were associated with colorectal polyps. No significant difference in BMI between the two groups (p>0.05).\u0000 \u0000 \u0000 \u0000 The incidence and progression of colorectal polyps are linked to serum lipid molecules and their derivative indexes. Dyslipidemia may increase the risk of colorectal polyps, potentially leading to colorectal cancer (CRC).\u0000","PeriodicalId":502333,"journal":{"name":"Advances in Laboratory Medicine / Avances en Medicina de Laboratorio","volume":"2 4","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-04-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140653100","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
En el laboratorio clínico, la calibración de los procedimientos de medición es un aspecto clave a la hora de garantizar la fiabilidad de los resultados del paciente. A lo largo de los años, se han publicado multitud de publicaciones y procedimientos para la evaluación del control de calidad y la interpretación de sus resultados. En esta publicación, nos centraremos en un aspecto crítico, la calibración, ya que no existen publicaciones o directrices claras sobre metodologías de calibración. Por lo general, solo están disponibles las recomendaciones del fabricante del reactivo o instrumento. El propósito de esta revisión es ahondar en esta deficiencia, con el fin de suscitar un debate y mejorar la situación actual.
{"title":"Calibración, un componente subestimado del proceso analítico en el laboratorio clínico","authors":"Oswald Sonntag, Tze Ping Loh","doi":"10.1515/almed-2023-0147","DOIUrl":"https://doi.org/10.1515/almed-2023-0147","url":null,"abstract":"\u0000 En el laboratorio clínico, la calibración de los procedimientos de medición es un aspecto clave a la hora de garantizar la fiabilidad de los resultados del paciente. A lo largo de los años, se han publicado multitud de publicaciones y procedimientos para la evaluación del control de calidad y la interpretación de sus resultados. En esta publicación, nos centraremos en un aspecto crítico, la calibración, ya que no existen publicaciones o directrices claras sobre metodologías de calibración. Por lo general, solo están disponibles las recomendaciones del fabricante del reactivo o instrumento. El propósito de esta revisión es ahondar en esta deficiencia, con el fin de suscitar un debate y mejorar la situación actual.","PeriodicalId":502333,"journal":{"name":"Advances in Laboratory Medicine / Avances en Medicina de Laboratorio","volume":"40 15","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140701608","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Nuria Padilla Apuntate, Carmen G. Puerto Cabeza, Alba Gallego Royo, Nuria Goñi Ros, Claudia Abadía Molina, Javier Acha Pérez, Pilar Calmarza
La prevalencia de la diabetes mellitus tipo 2 (DMT2) está aumentando de forma exponencial en todo el mundo, habiéndose comprobado que estos pacientes tienen mayor riesgo de presentar fracturas óseas, con respecto a la población sana, por lo que resulta de gran relevancia el conocimiento del efecto de los fármacos antidiabéticos sobre el metabolismo óseo. Estudio estadístico descriptivo, retrospectivo, de 106 pacientes en tratamiento con seis grupos de fármacos antidiabéticos: insulina, inhibidores de dipeptidilpeptidasa 4 (iDPP4), agonistas del receptor del péptido similar al glucagón tipo 1 (arGLP1), sulfonilureas, inhibidores del cotransportador de sodio-glucosa tipo 2 (iSGLT2) y pioglitazona, en los que se determinaron osteocalcina (OC), fosfatasa alcalina ósea (FAO) y telopéptido C-terminal del colágeno tipo 1 o beta-crosslaps (β-CTx). Se encontraron concentraciones más elevadas de β-CTx en los pacientes tratados con pioglitazona que en los tratados con iDPP4 (p=0,035), iSGLT2 (p=0,020) y con arGLP1 (p<0,001), siendo los pacientes tratados con arGLP1 los que presentaron las concentraciones más bajas de β-CTx. El tipo de tratamiento antidiabético recibido en pacientes que padecen DMT2 puede afectar el remodelado óseo. En nuestro estudio los pacientes que fueron tratados con pioglitazona mostraron las concentraciones más elevadas de β-CTx con respecto al resto de grupos de fármacos, lo cual parece indicar la conveniencia de evitar estos fármacos, sobre todo en mujeres postmenopáusicas con DMT2. Los fármacos arGLP1 presentaron los valores más bajos de β-CTx, por lo que podrían ejercer un efecto beneficioso sobre el metabolismo óseo.
{"title":"Estudio del efecto del tratamiento con fármacos antidiabéticos sobre el metabolismo óseo","authors":"Nuria Padilla Apuntate, Carmen G. Puerto Cabeza, Alba Gallego Royo, Nuria Goñi Ros, Claudia Abadía Molina, Javier Acha Pérez, Pilar Calmarza","doi":"10.1515/almed-2024-0033","DOIUrl":"https://doi.org/10.1515/almed-2024-0033","url":null,"abstract":"\u0000 \u0000 \u0000 La prevalencia de la diabetes mellitus tipo 2 (DMT2) está aumentando de forma exponencial en todo el mundo, habiéndose comprobado que estos pacientes tienen mayor riesgo de presentar fracturas óseas, con respecto a la población sana, por lo que resulta de gran relevancia el conocimiento del efecto de los fármacos antidiabéticos sobre el metabolismo óseo.\u0000 \u0000 \u0000 \u0000 Estudio estadístico descriptivo, retrospectivo, de 106 pacientes en tratamiento con seis grupos de fármacos antidiabéticos: insulina, inhibidores de dipeptidilpeptidasa 4 (iDPP4), agonistas del receptor del péptido similar al glucagón tipo 1 (arGLP1), sulfonilureas, inhibidores del cotransportador de sodio-glucosa tipo 2 (iSGLT2) y pioglitazona, en los que se determinaron osteocalcina (OC), fosfatasa alcalina ósea (FAO) y telopéptido C-terminal del colágeno tipo 1 o beta-crosslaps (β-CTx).\u0000 \u0000 \u0000 \u0000 Se encontraron concentraciones más elevadas de β-CTx en los pacientes tratados con pioglitazona que en los tratados con iDPP4 (p=0,035), iSGLT2 (p=0,020) y con arGLP1 (p<0,001), siendo los pacientes tratados con arGLP1 los que presentaron las concentraciones más bajas de β-CTx.\u0000 \u0000 \u0000 \u0000 El tipo de tratamiento antidiabético recibido en pacientes que padecen DMT2 puede afectar el remodelado óseo. En nuestro estudio los pacientes que fueron tratados con pioglitazona mostraron las concentraciones más elevadas de β-CTx con respecto al resto de grupos de fármacos, lo cual parece indicar la conveniencia de evitar estos fármacos, sobre todo en mujeres postmenopáusicas con DMT2. Los fármacos arGLP1 presentaron los valores más bajos de β-CTx, por lo que podrían ejercer un efecto beneficioso sobre el metabolismo óseo.\u0000","PeriodicalId":502333,"journal":{"name":"Advances in Laboratory Medicine / Avances en Medicina de Laboratorio","volume":" 15","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-03-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140384253","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Patricia Ramos Mayordomo, Marta Capilla Díez, Danay Areli Ticona Espinoza, María Verónica Torres Jaramillo, Nathalie Martínez Tejeda, Thalia Gloria Ticona Espinoza, Cristina Colmenero Calleja, Virginia Fraile Gutiérrez
La microangiopatía trombótica (MAT) se define por trombocitopenia, anemia hemolítica microangiopática y daño de órganos diana. El embarazo está asociado con varias formas de MAT como preeclampsia (PE), síndrome de HELLP, púrpura trombótica trombocitopénica (PTT) y síndrome hemolítico urémico (SHU). Cuando SHU se produce por desregulación de la vía alternativa del complemento se denomina SHU atípico (SHUa). El diagnóstico diferencial es complejo, ya que comparten características clínicas, siendo importante realizarlo precozmente para instaurar tratamiento específico y mejorar el pronóstico. Primigesta de 43 años ingresa a la edad gestacional de 33 semanas, con diagnóstico de preeclampsia grave y sufrimiento fetal por lo que se realiza cesárea urgente. En el puerperio inmediato, presenta insuficiencia hepática aguda y fracaso renal anúrico en contexto de síndrome de HELLP, anemia, trombopenia, hipertensión arterial (HTA) y alteraciones neurológicas. Se realiza estudio de MAT y diagnóstico diferencial evidenciando además SHUa asociado al embarazo. Se inicia tratamiento con Eculizumab presentando buena respuesta y progresiva mejoría clínica y analítica. El SHUa es una enfermedad rara y multifactorial con elevada mortalidad antes de la aparición del Eculizumab. Debido al complejo diagnóstico, el laboratorio clínico tiene un papel clave en el diagnóstico diferencial y abordaje.
{"title":"Microangiopatía trombótica (MAT) asociada al embarazo: papel del laboratorio clínico en el diagnóstico diferencial","authors":"Patricia Ramos Mayordomo, Marta Capilla Díez, Danay Areli Ticona Espinoza, María Verónica Torres Jaramillo, Nathalie Martínez Tejeda, Thalia Gloria Ticona Espinoza, Cristina Colmenero Calleja, Virginia Fraile Gutiérrez","doi":"10.1515/almed-2023-0138","DOIUrl":"https://doi.org/10.1515/almed-2023-0138","url":null,"abstract":"\u0000 \u0000 \u0000 La microangiopatía trombótica (MAT) se define por trombocitopenia, anemia hemolítica microangiopática y daño de órganos diana. El embarazo está asociado con varias formas de MAT como preeclampsia (PE), síndrome de HELLP, púrpura trombótica trombocitopénica (PTT) y síndrome hemolítico urémico (SHU). Cuando SHU se produce por desregulación de la vía alternativa del complemento se denomina SHU atípico (SHUa). El diagnóstico diferencial es complejo, ya que comparten características clínicas, siendo importante realizarlo precozmente para instaurar tratamiento específico y mejorar el pronóstico.\u0000 \u0000 \u0000 \u0000 Primigesta de 43 años ingresa a la edad gestacional de 33 semanas, con diagnóstico de preeclampsia grave y sufrimiento fetal por lo que se realiza cesárea urgente. En el puerperio inmediato, presenta insuficiencia hepática aguda y fracaso renal anúrico en contexto de síndrome de HELLP, anemia, trombopenia, hipertensión arterial (HTA) y alteraciones neurológicas. Se realiza estudio de MAT y diagnóstico diferencial evidenciando además SHUa asociado al embarazo. Se inicia tratamiento con Eculizumab presentando buena respuesta y progresiva mejoría clínica y analítica.\u0000 \u0000 \u0000 \u0000 El SHUa es una enfermedad rara y multifactorial con elevada mortalidad antes de la aparición del Eculizumab. Debido al complejo diagnóstico, el laboratorio clínico tiene un papel clave en el diagnóstico diferencial y abordaje.\u0000","PeriodicalId":502333,"journal":{"name":"Advances in Laboratory Medicine / Avances en Medicina de Laboratorio","volume":" 16","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-03-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140213877","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pika Meško Brguljan, M. Thelen, Francisco A. Bernabeu-Andreu, Christos Kroupis, Guilaine Boursier, Ines Vukasović, Edward Barrett, Duilio Brugnoni, Maria Lohmander, Luděk Šprongl, Tatjana Vodnik, Irina Ghiţă, Florent Vanstapel, Michel Vaubourdolle, Willem Huisman
Gran parte de la actividad en el laboratorio clínico debe quedar documentada para facilitar el mantenimiento de la calidad del servicio, lo que deriva en la generación de una gran cantidad de documentación, formularios e informes. Con tal objeto, es necesario especificar el tiempo de retención requerido para cada tipo de documento y muestra. Además de la obligación de conservar los informes del laboratorio clínico como parte de la historia clínica de los pacientes, el laboratorio también está obligado por ley, o según las directrices de las organizaciones profesionales, si las hubiera, a retener un gran volumen de documentación y muestras. En caso contrario, la dirección del laboratorio deberá establecer un calendario de retención, en el que se especifiquen las condiciones y el periodo de conservación, de acuerdo con los requisitos de la norma ISO 15189:2022 sobre retención de documentación y registros de gestión de la calidad. En el presente proyecto, el Grupo de Trabajo de la EFLM sobre Acreditación y Normas ISO/CEN propone una serie de periodos de retención de documentación y muestras, basada en la metodología de análisis modal de fallos y efectos (AMFE), un método para la reducción de riesgos que ha pasado a formar parte integral de los estándares actuales.
临床实验室的许多活动都必须记录在案，以便于保持服务质量，因此会产生大 量的文件、表格和报告。为此，有必要规定各类文件和样本所需的保存时间。除了有义务将临床化验报告作为患者病历的一部分加以保存外，法律或专业组织的指导原则（如有）也规定化验室有义务保存大量文件和样本。如果不是这种情况，实验室管理层应根据 ISO 15189:2022 中关于质量管理文件和记录的保存要求，制定保存计划，明确保存条件和保存期限。在本项目中，欧洲实验室实验室管理委员会认证和 ISO/CEN 标准工作组根据故障模式和影响分析 (FMEA) 方法，提出了一套文件和样品的保存期限，该方法是一种降低风险的方法，已成为现行标准的组成部分。
{"title":"Grupo de Trabajo de la EFLM sobre Acreditación y Normas ISO/CEN sobre cómo abordar los requisitos de la norma ISO15189 sobre retención de documentación y muestras","authors":"Pika Meško Brguljan, M. Thelen, Francisco A. Bernabeu-Andreu, Christos Kroupis, Guilaine Boursier, Ines Vukasović, Edward Barrett, Duilio Brugnoni, Maria Lohmander, Luděk Šprongl, Tatjana Vodnik, Irina Ghiţă, Florent Vanstapel, Michel Vaubourdolle, Willem Huisman","doi":"10.1515/almed-2024-0020","DOIUrl":"https://doi.org/10.1515/almed-2024-0020","url":null,"abstract":"\u0000 Gran parte de la actividad en el laboratorio clínico debe quedar documentada para facilitar el mantenimiento de la calidad del servicio, lo que deriva en la generación de una gran cantidad de documentación, formularios e informes. Con tal objeto, es necesario especificar el tiempo de retención requerido para cada tipo de documento y muestra. Además de la obligación de conservar los informes del laboratorio clínico como parte de la historia clínica de los pacientes, el laboratorio también está obligado por ley, o según las directrices de las organizaciones profesionales, si las hubiera, a retener un gran volumen de documentación y muestras. En caso contrario, la dirección del laboratorio deberá establecer un calendario de retención, en el que se especifiquen las condiciones y el periodo de conservación, de acuerdo con los requisitos de la norma ISO 15189:2022 sobre retención de documentación y registros de gestión de la calidad.\u0000 En el presente proyecto, el Grupo de Trabajo de la EFLM sobre Acreditación y Normas ISO/CEN propone una serie de periodos de retención de documentación y muestras, basada en la metodología de análisis modal de fallos y efectos (AMFE), un método para la reducción de riesgos que ha pasado a formar parte integral de los estándares actuales.","PeriodicalId":502333,"journal":{"name":"Advances in Laboratory Medicine / Avances en Medicina de Laboratorio","volume":"90 S78","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-03-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140257149","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
José Cuenca Alcocel, Lorena Villalba-Heredia, Inés Martínez Redondo, Clara Berrozpe-Villabona, J. Casajús, J. Arbonés-Mainar, Pilar Calmarza
Bone mass progressively increases to peak during childhood and adolescence, which determines future bone health. Bone formation–resorption processes are assessed using bone markers. However, studies on the impact of obesity on bone turnover markers at this age are limited, and results are inconsistent. The objective of this study was to examine the potential impact of overweight/obesity on bone metabolism. A study was performed to compare parameters of bone metabolism in 45 girls and boys with normal weight (controls) and in a group of 612 girls and boys with overweight/obesity (cases) from the Exergames study (University of Zaragoza). Ages ranged from 8 to 12 years. Higher values of phosphorus and IGFBP-3 were observed in children with overweight/obesity, as compared to children with normal weight, (p=0.042) and (p=0.042), respectively. BAP, osteocalcin, magnesium, vitamin D and IGF-I concentrations were lower in the group with overweight/obesity, whereas calcium concentrations were higher in this group, although differences were not statistically significant. A negative correlation was found (r=−0.193) (p=0.049) between BAP and BMI. Although differences did not reach statistical significance, BAP and osteocalcin concentrations were lower in children with overweight/obesity. This added to the negative correlation found between BAP and MIC may demonstrate that overweight/obesity may negatively affect bone health already at a young age.
{"title":"Bone metabolism in children with normal weight and overweight/obesity in a northeastern region of Spain","authors":"José Cuenca Alcocel, Lorena Villalba-Heredia, Inés Martínez Redondo, Clara Berrozpe-Villabona, J. Casajús, J. Arbonés-Mainar, Pilar Calmarza","doi":"10.1515/almed-2024-0026","DOIUrl":"https://doi.org/10.1515/almed-2024-0026","url":null,"abstract":"\u0000 \u0000 \u0000 Bone mass progressively increases to peak during childhood and adolescence, which determines future bone health. Bone formation–resorption processes are assessed using bone markers. However, studies on the impact of obesity on bone turnover markers at this age are limited, and results are inconsistent. The objective of this study was to examine the potential impact of overweight/obesity on bone metabolism.\u0000 \u0000 \u0000 \u0000 A study was performed to compare parameters of bone metabolism in 45 girls and boys with normal weight (controls) and in a group of 612 girls and boys with overweight/obesity (cases) from the Exergames study (University of Zaragoza). Ages ranged from 8 to 12 years.\u0000 \u0000 \u0000 \u0000 Higher values of phosphorus and IGFBP-3 were observed in children with overweight/obesity, as compared to children with normal weight, (p=0.042) and (p=0.042), respectively. BAP, osteocalcin, magnesium, vitamin D and IGF-I concentrations were lower in the group with overweight/obesity, whereas calcium concentrations were higher in this group, although differences were not statistically significant. A negative correlation was found (r=−0.193) (p=0.049) between BAP and BMI.\u0000 \u0000 \u0000 \u0000 Although differences did not reach statistical significance, BAP and osteocalcin concentrations were lower in children with overweight/obesity. This added to the negative correlation found between BAP and MIC may demonstrate that overweight/obesity may negatively affect bone health already at a young age.\u0000","PeriodicalId":502333,"journal":{"name":"Advances in Laboratory Medicine / Avances en Medicina de Laboratorio","volume":"47 3","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-03-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140257323","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Bone remodeling markers: monitoring the changing bone","authors":"N. Varo","doi":"10.1515/almed-2024-0009","DOIUrl":"https://doi.org/10.1515/almed-2024-0009","url":null,"abstract":"","PeriodicalId":502333,"journal":{"name":"Advances in Laboratory Medicine / Avances en Medicina de Laboratorio","volume":"38 17","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-02-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140426069","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：